C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

Slides:

Advertisements

Similar presentations

The results of the SHARP trial. SHARP: Rationale Risk of vascular events is high among patients with chronic kidney disease Lack of clear association.

Advertisements

The results of the Study of Heart and Renal Protection (SHARP)

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.

Flow chart showing number of citations retrieved by individual searches and number of trials included in review Strippoli GF, et al. BMJ 2008 Feb 25 [Epub.

SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ﬀ ects of lowering LDL cholesterol with simvastatin plus.

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

LDL and cardiovascular disease: Latest insights

The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.

HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events Jane Armitage on behalf of the THRIVE Collaborative Group Financial Disclosure:

HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.

The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.

Plasma Homocysteine and Coronary Heart Disease David S. Rosenblatt, MD Department of Human Genetics McGill University.

Scandinavian Simvastatin Survival Study (4S) The Lancet, Vol 344, November 19, 1994.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]

Cholesterol Treatment Trialists’ (CTT) Collaboration. Lancet 2010;epub 9 Nov.

Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Baseline characteristics and eligibility criteria of participating trials Cholesterol Treatment Trialists’ (CTT) Collaborators Lancet 2005;366:

Date of download: 6/10/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Homocysteine-Lowering With Folic Acid.

Baseline characteristics of HPS participants by prior cerebrovascular disease.

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;

Volume 376, Issue 9753, Pages (November 2010)

The ALERT Trial.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

LDL cholesterol in CKD—to treat or not to treat?

Predicted 5-year benefits of LDL cholesterol reductions with statin treatment at different levels of risk. (A) Major vascular events, and (B) vascular.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

SEARCH Collaborative Group. Lancet 2010;epub 9 Nov

Scandinavian Simvastatin Survival Study (4S)

Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group

Baseline characteristics of HPS participants by prior diabetes

TNT Study: Baseline Characteristics of the Patients

The results of the SHARP trial

Volume 377, Issue 9784, Pages (June 2011)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta- analysis of individual participant data from randomised trials

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]

Volume 376, Issue 9753, Pages (November 2010)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Volume 382, Issue 9894, Pages (August 2013)

LDL cholesterol in CKD—to treat or not to treat?

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

Cause of death Treatment-arm events, % (n=45 054)

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Relative Risk of Onset of Cancer from the Cholesterol Treatment Trialists’ (CTT) Meta-Analysis of Statin Trials, According to Year of Onset Risk ratios.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

The results of the SHARP trial

PROSPER: trial design

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Lipids, the Heart, and the Kidney

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June

Trial Profile

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Baseline demographic features and laboratory measurements by treatment allocation

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Average use of study simvastatin plus ezetimibe or non-study statin and average change in plasma LDL cholesterol from baseline, by period of follow-up

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Major atherosclerotic events subdivided by type

C. Baigent, et al. Lancet 2011;Epub 9 June Major atherosclerotic events by baseline characteristics χ² tests on 1 degree of freedom are shown for heterogeneity between rate ratios within dichotomous categories and for trend within other categories. BP=blood pressure. MDRD=Modifi ed Diet in Renal Disease formula.17 GFR=glomerular fi ltration rate

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Cause-specific and overall mortality

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Cancer incidence and cancer mortality by site

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system

C. Baigent, et al. Lancet 2011;Epub 9 June Effects of LDL-lowering therapy on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials in other patients Data from the Cholesterol Treatment Trialists’ Collaboration. χ² tests are shown for eterogeneity between rate ratios for each outcome in the four trials (4D, ALERT, AURORA, and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol.